PMID- 37036954
OWN - NLM
STAT- Publisher
LR  - 20230410
IS  - 2046-5556 (Electronic)
IS  - 0264-8725 (Linking)
DP  - 2023 Apr 10
TI  - Study on Undercarboxylated Osteocalcin in Improving Cognitive Function of Rats 
      with Type 2 Diabetes Mellitus by Regulating PI3K-AKT-GSK/3beta Signaling 
      Pathwaythrough medical images.
PG  - 1-16
LID - 10.1080/02648725.2023.2199238 [doi]
AB  - This paper aims to clarify the effect of Undercarboxylated osteocalcin (ucOC) on 
      cognitive function in rats with type 2 diabetes mellitus (T2DM). This research 
      reviewed the cognitive function of 35 diabetic patients, 33 non-diabetic patients 
      and the serum levels of Undercarboxylated osteocalcin (ucOC) in patients. What's 
      more, we analyzed the correlation between serum ucOC levels and cognitive 
      function. Diabetic rats were treated with high (30 mug.kg(-1).d(-1)) and low 
      (10 mug.kg(-1).d(-1)) doses of ucOC to investigate its effects in regulating ucOC 
      on blood lipid, blood glucose and cognitive function. We systematically detected 
      the phosphorylation levels of cognitive level-related proteins (PI3K, AKT, and 
      GSK/3beta) in the hippocampus by Western Blot. Finally, PI3K-Akt pathway involved in 
      regulating cognitive function in diabetic rats by ucOC was verified with AKT 
      pathway inhibitor LY294002. MoCA score and serum ucOC levels were significantly 
      reduced in patients with diabetes mellitus. ucOC could 
      concentration-dose-dependently decrease the blood glucose and lipid levels, and 
      improve glucose metabolism and weaken insulin resistance in diabetic rats 
      (P < 0.001). In addition, escape latency in diabetic rats was significantly 
      higher than that of normal rats in the Morris maze test, and ucOC 
      dose-dependently shortened the escape latency in diabetic rats (all with 
      P < 0.05). After using AKT pathway inhibitor, ucOC failed to shorten the escape 
      latency in diabetic rats. In conclusion, this study explored the relevant 
      mechanisms in inducing cognitive dysfunction of T2DM, suggesting the potential 
      value of ucOC as a drug to improve cognitive dysfunction in patients with T2DM in 
      clinical.
FAU - Zhao, Yu
AU  - Zhao Y
AD  - Department of Geriatrics, the Third Affiliated Hospital of Qiqihar Medical 
      University, Qiqihar, China.
FAU - Yang, Lili
AU  - Yang L
AD  - Department of Cardiology, the Third Affiliated Hospital of Qiqihar Medical 
      University, Qiqihar, China.
FAU - Chen, Mei
AU  - Chen M
AD  - Department of Geriatrics, the Third Affiliated Hospital of Qiqihar Medical 
      University, Qiqihar, China.
FAU - Gao, Feng
AU  - Gao F
AD  - Department of Neurology, the Third Affiliated Hospital of Qiqihar Medical 
      University, Qiqihar, China.
FAU - Lv, Yinghui
AU  - Lv Y
AD  - Department of Geriatrics, the Third Affiliated Hospital of Qiqihar Medical 
      University, Qiqihar, China.
FAU - Li, Xue
AU  - Li X
AD  - Department of Geriatrics, the Third Affiliated Hospital of Qiqihar Medical 
      University, Qiqihar, China.
FAU - Liu, Hongmin
AU  - Liu H
AD  - School of Nursing, Qiqihar Medical University, Qiqihar, China.
LA  - eng
PT  - Journal Article
DEP - 20230410
PL  - England
TA  - Biotechnol Genet Eng Rev
JT  - Biotechnology & genetic engineering reviews
JID - 8510274
SB  - IM
OTO - NOTNLM
OT  - Morris maze test
OT  - PI3K-AKT-GSK/3beta signaling pathway
OT  - T2DM
OT  - Undercarboxylated osteocalcin
EDAT- 2023/04/11 06:00
MHDA- 2023/04/11 06:00
CRDT- 2023/04/10 15:12
PHST- 2023/04/10 15:12 [entrez]
PHST- 2023/04/11 06:00 [pubmed]
PHST- 2023/04/11 06:00 [medline]
AID - 10.1080/02648725.2023.2199238 [doi]
PST - aheadofprint
SO  - Biotechnol Genet Eng Rev. 2023 Apr 10:1-16. doi: 10.1080/02648725.2023.2199238.